Related Experiment Video
Updated: May 20, 2026
08:48
Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
Published on: June 30, 2023
Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes
Kristina Leuner1, Kathrin Schulz, Tanja Schütt
1Clinical and Molecular Pharmacy, Erlangen University, Erlangen, Germany.
Molecular Neurobiology
|July 24, 2012
Summary
Mitochondrial dysfunction and oxidative stress are early indicators of Alzheimer's disease (AD). Blood cell analysis reveals decreased mitochondrial membrane potential in AD and mild cognitive impairment (MCI) patients.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing significant neuronal loss.
- Pathological hallmarks include synaptic and neuronal loss, atrophy, and neurotransmitter depletion.
- Mitochondrial dysfunction and oxidative stress are increasingly implicated in AD pathogenesis.
Purpose of the Study:
- To explore the potential of peripheral markers for AD detection.
- To investigate mitochondrial dysfunction and oxidative stress in blood cells, specifically lymphocytes, as biomarkers for AD.
- To assess apoptosis, oxidative stress, and mitochondrial function in AD detection.
Main Methods:
- Analysis of complex activities of the respiratory chain in lymphocytes.
- Measurement of mitochondrial membrane potential (MMP) in blood cells.
- Assessment of sensitivity to respiratory chain complex inhibitors.
Main Results:
- Decreased basal MMP levels were observed in lymphocytes from AD patients.
- Lymphocytes from AD patients showed enhanced sensitivity to respiratory chain complex inhibitors.
- Mitochondrial alterations were also detected in patients with mild cognitive impairment (MCI).
Conclusions:
- Mitochondrial dysfunction serves as a potential early peripheral marker for AD detection.
- Mitochondrial alterations in lymphocytes correlate with AD pathology observed in the brain.
- These findings suggest MMP and respiratory chain activity as valuable biomarkers for early AD and MCI diagnosis.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...